Arvinas Holding Company (ARVN)
NASDAQ:ARVN
Top Page
Arvinas Holding Company
(NASDAQ:ARVN)
Select Model
Select Model
Rating:48Neutral
Price Target:
$11.00
▲(0.73% Upside)
Action:ReiteratedDate:03/19/26
The score is held down primarily by weak financial performance (ongoing losses, significant cash burn, and 2025 gross profit anomaly) and bearish technical signals (below key moving averages with negative MACD). Pipeline and catalyst messaging (earnings call and ARV-102 Phase 1 update) provide support but are tempered by the sharply reduced cash position and execution/partnering risk.
Positive Factors
PROTAC platform and diversified clinical pipeline
Arvinas’ core PROTAC platform and multiple clinical-stage programs materially reduce binary program risk versus a single-asset profile. Sustained pipeline breadth (LRRK2, KRAS, BCL6, polyQ) supports long-term upside from multiple potential clinical readouts, partnership paths, and eventual commercialization options if trials succeed.
Negative Factors
Sharp cash depletion and financing sensitivity
A ~91% year-over-year decline in cash creates structural sensitivity to upcoming milestones and partner deals. Even with cost cuts, the much smaller cash buffer increases the likelihood of equity raises, partnerships or contract-reliant funding, which can affect long-term program continuity and strategic optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
PROTAC platform and diversified clinical pipeline
Arvinas’ core PROTAC platform and multiple clinical-stage programs materially reduce binary program risk versus a single-asset profile. Sustained pipeline breadth (LRRK2, KRAS, BCL6, polyQ) supports long-term upside from multiple potential clinical readouts, partnership paths, and eventual commercialization options if trials succeed.
Read all positive factors
Arvinas Holding Company (ARVN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$698.45M
Dividend YieldN/A
Average Volume (3M)902.91K
Price to Earnings (P/E)―
Beta (1Y)1.21
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees430
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.10
Shares Outstanding63,961,000
10 Day Avg. Volume1,007,269
30 Day Avg. Volume902,914
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)1.77
Price to Sales (P/S)2.93
P/FCF Ratio-2.79
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue2.15
Enterprise Value/Gross Profit2.16
Enterprise Value/Ebitda-5.78
Forecast
1Y Price Target
$16.45Price Target Upside50.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)-3.37
Revenue Forecast (FY)$93.17M
Arvinas Holding Company Business Overview & Revenue Model
Company Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting ...
How the Company Makes Money
Arvinas primarily makes money through biopharmaceutical collaboration economics rather than product sales, because it is a clinical-stage company and, to the extent publicly available, does not rely on commercialized-product revenue. Its key reven...
Arvinas Holding Company Earnings Call Summary
Earnings Call Date:Feb 24, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Neutral
The call conveyed strong scientific and clinical momentum—multiple programs advancing, encouraging early biomarker and preclinical signals, and disciplined cost reductions—while simultaneously revealing material financial pressure from a steep decline in cash and a large quarter-over-quarter revenue drop. The company maintained guidance for cash runway into 2028 and emphasized partner discussions, but the balance sheet tightening and competitive landscape create meaningful execution and financing risk alongside the positive clinical developments.Positive Updates
Pipeline Advancement and Clinical Momentum
Four clinical-stage programs (ARV-102, ARV-806, ARV-393, ARV-027) ongoing with multiple readouts planned in 2026; first‑in‑human dosing initiated for ARV-027 (polyQ AR degrader) and ARV-6723 (HPK1) expected to enter clinic later in 2026.
Negative Updates
Sharp Decline in Cash Balance
Cash, cash equivalents and marketable securities fell to just over $85M at 12/31/2025 from just over $1.0B at the end of 2024 — an approximate decline of ~91% year-over-year, creating a heightened sensitivity to upcoming milestones, partner deals, or financing.
Read all updates
Q4-2025 Updates
Positive
Negative
Pipeline Advancement and Clinical Momentum
Four clinical-stage programs (ARV-102, ARV-806, ARV-393, ARV-027) ongoing with multiple readouts planned in 2026; first‑in‑human dosing initiated for ARV-027 (polyQ AR degrader) and ARV-6723 (HPK1) expected to enter clinic later in 2026.
Read all positive updates
Company Guidance
Arvinas guided that 2026 will be a catalyst year with multiple Phase 1 data readouts and clinical advances — expecting data from ARV‑102, ARV‑806 and ARV‑393, with ARV‑027 newly in the clinic and ARV‑6723 planned to enter first‑in‑human later in the year — and reiterated cash runway into 2028 after ending Q4 with just over $85M in cash and marketable securities (vs. just over $1.0B at 12/31/2024); Q4 revenue was $9.5M (vs. $59.2M), FY revenue was $262.6M (vs. $263.4M), Q4 G&A was $23.0M (non‑GAAP G&A $15.3M) and FY G&A $95.9M, Q4 R&D was $61.1M (non‑GAAP R&D $56.5M) and FY R&D $285.2M, with total non‑GAAP expenses of $71.8M in Q4 and $323.4M for the year; the board had authorized up to $100M for buybacks and repurchased ~10M shares at an average $9.09 per share for ~$91.9M (program now suspended); clinically the company highlighted specific metrics/targets including >50% CSF LRRK2 reduction for ARV‑102 (AD/PD presentation), >25‑fold preclinical potency for ARV‑806 versus clinical inhibitors and a need to exceed ~35% response benchmarks in the G12D space, ARV‑393 responses in early cohorts at exposures below predicted efficacious levels plus preclinical combo tumor growth inhibition of 91% vs 36% for glofitamab alone, and plans to select a commercialization partner for vepdegestrant ahead of the June 5 PDUFA date.Arvinas Holding Company Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 262.60M | 263.40M | 78.50M | 131.40M | 53.60M |
| Gross Profit | 257.40M | 263.40M | 78.50M | 131.40M | 53.60M |
| EBITDA | -75.30M | -243.60M | -394.80M | -255.00M | -182.40M |
| Net Income | -80.80M | -198.90M | -367.30M | -282.50M | -191.00M |
Balance Sheet | |||||
| Total Assets | 717.90M | 1.09B | 1.30B | 1.27B | 1.58B |
| Cash, Cash Equivalents and Short-Term Investments | 685.40M | 1.04B | 1.26B | 1.21B | 1.50B |
| Total Debt | 8.50M | 9.70M | 3.20M | 5.50M | 5.00M |
| Total Liabilities | 284.00M | 529.70M | 644.60M | 703.90M | 799.90M |
| Stockholders Equity | 433.90M | 561.70M | 660.00M | 564.90M | 781.70M |
Cash Flow | |||||
| Free Cash Flow | -275.70M | -261.10M | -350.70M | -280.30M | 554.70M |
| Operating Cash Flow | -273.80M | -259.30M | -347.80M | -273.50M | 559.40M |
| Investing Cash Flow | 407.60M | 34.70M | 203.50M | 242.80M | -1.31B |
| Financing Cash Flow | -91.40M | 7.90M | 374.70M | 4.70M | 278.60M |
Arvinas Holding Company Technical Analysis
Neutral
10.92
Price Trends
12.61
Negative
12.13
Negative
10.06
Positive
Market Momentum
-0.59
Positive
37.97
Neutral
14.93
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARVN, the sentiment is Neutral. The current price of 10.92 is below the 20-day moving average (MA) of 12.43, below the 50-day MA of 12.61, and above the 200-day MA of 10.06, indicating a neutral trend. The MACD of -0.59 indicates Positive momentum. The RSI at 37.97 is Neutral, neither overbought nor oversold. The STOCH value of 14.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ARVN.
Arvinas Holding Company Risk Analysis
Arvinas Holding Company disclosed 69 risk factors in its most recent earnings report. Arvinas Holding Company reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Arvinas Holding Company Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $1.88B | -101.81 | 1813.84% | ― | 196.42% | 53.92% | |
56 Neutral | $1.18B | -5.93 | -27.17% | ― | ― | -103.95% | |
52 Neutral | $988.68M | -12.74 | -43.61% | ― | -100.00% | -28.79% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $698.45M | -9.53 | -14.25% | ― | ― | ― | |
47 Neutral | $613.34M | -3.30 | -1065.47% | ― | 96.83% | -61.92% | |
47 Neutral | $1.24B | -13.39 | -42.90% | ― | ― | 17.23% |
* Healthcare Sector Average
ARVN
Arvinas Holding Company
10.92
2.97
37.36%
ANAB
AnaptysBio
65.39
47.20
259.48%
MGTX
Meiragtx Holdings
7.62
0.39
5.39%
CMPX
Compass Therapeutics
5.49
3.45
169.12%
OLMA
Olema Pharmaceuticals
14.17
10.03
242.27%
BCAX
Bicara Therapeutics Inc.
18.68
5.58
42.60%
Arvinas Holding Company Corporate Events
Business Operations and StrategyProduct-Related Announcements
Arvinas Reports Positive Phase 1 Data for ARV-102
Positive
Mar 18, 2026
Arvinas, Inc., a clinical-stage biotech focused on PROTAC-based targeted protein degradation, reported positive Phase 1 data on March 18, 2026, for ARV-102, an oral LRRK2 degrader designed to cross the blood-brain barrier in Parkinson’s dise...
Business Operations and StrategyExecutive/Board Changes
Arvinas Announces Leadership Transition and New CEO Appointment
Neutral
Feb 12, 2026
On February 10, 2026, Arvinas president, CEO and board chair John Houston, Ph.D., notified the company he would resign from those roles effective February 12, 2026, while remaining on the board and transitioning to a consulting position through Ma...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.